Corvus Pharmaceuticals, Inc. (CRVS) intrinsic value & 10-year financials
Corvus Pharmaceuticals, Inc. (CRVS) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.52
- Market cap
- $759.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -70.4%
- Free cash flow (FY2025)
- -$33.0M
CRVS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$15.3M | -$0.53 | -$33.0M | — | -104.9% |
| FY2024 | — | -$62.3M | -$1.02 | — | — | -111.2% |
| FY2023 | — | -$27.0M | -$0.56 | -$24.0M | — | -52.8% |
| FY2022 | — | -$41.3M | -$0.89 | -$27.3M | — | -80.8% |
| FY2021 | — | -$43.2M | -$1.03 | -$36.7M | — | -82.9% |
| FY2020 | — | -$6.0M | -$0.20 | -$34.9M | — | -69.9% |
| FY2019 | — | -$46.7M | -$1.59 | -$37.3M | — | -71.6% |
| FY2018 | — | -$46.9M | — | -$41.3M | — | -50.4% |
| FY2017 | — | -$55.7M | — | -$46.5M | — | -51.9% |
| FY2016 | — | -$36.4M | — | -$30.1M | — | -27.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Corvus Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Corvus Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -82.0% ROIC.
Corvus Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Corvus Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.